Urinary Tract Infection News and Research RSS Feed - Urinary Tract Infection News and Research

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.

Potty training right from the birth can eliminate need for diapers

Western babies are potty trained later these days and need diapers until an average of three years of age. But even infants can be potty trained. A study by researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, followed 47 infants and their mothers in Vietnam - where potty training starts at birth and the need for diapers is usually eliminated by nine months of age. [More]
FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. [More]

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets. [More]
FDA approves Allergan’s BOTOX to treat overactive bladder

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication. [More]

Allergan receives FDA approval for Botox to treat overactive bladder

The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics. [More]
FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. [More]
Little to choose between catheter types for intermittent self-catheterization

Little to choose between catheter types for intermittent self-catheterization

Patients undertaking intermittent self catheterization for urinary retention should be offered the choice of clean noncoated, hydrophilic, or gel reservoir catheters, say researchers who found none offers a strong advantage in avoiding urinary tract infection. [More]

Primary-care clinic treatment improves patient follow up

Treating low-acuity emergency-department patients in a primary-care clinic results in better future primary care follow up, research shows. [More]
Repeated toxin treatment sustains benefits in incontinence patients

Repeated toxin treatment sustains benefits in incontinence patients

Repeated treatment with onabotulinumtoxinA consistently reduces urinary incontinence episodes in patients with neurogenic detrusor overactivity, show findings from an extension study of Phase III trials. [More]
Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). [More]
Indraprastha Apollo Hospital installs bioMerieux's MALDI-TOF-VITEK MS system in India

Indraprastha Apollo Hospital installs bioMerieux's MALDI-TOF-VITEK MS system in India

Indraprastha Apollo Hospitals, New Delhi, today installed a first-of-its-kind cutting edge technology bioMerieux's MALDI-TOF-VITEK MS system in India - a rapidly automated microbial identification system that identifies disease-causing microorganisms such as bacteria and fungi so that correct diagnosis and early treatment is achieved. [More]

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy. [More]
Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate). [More]

Thulium vapoenucleation well-tolerated for treating benign prostate obstruction

Treating benign prostate obstruction with thulium vapoenucleation of the prostate is well-tolerated and effective and leads to a low incidence of perioperative complications, according to recent study findings. [More]

Antimicrobial catheters do not significantly reduce UTI risk

Silver alloy-coated antimicrobial catheters do not significantly reduce the risk for catheter-associated urinary tract infection compared with standard catheters in adult hospital patients requiring short-term catheterization, show UK study results. [More]

Administrative data quantify hospital infection risk

Administrative hospital data can successfully quantify the incidence of healthcare-associated urinary tract infection, indicating the data's potential use for risk monitoring and surveillance of this frequent occurrence, show systematic review results. [More]
Neurologist care lowers risk for PD-related hospitalizations

Neurologist care lowers risk for PD-related hospitalizations

Regular care by a neurologist lowers the risk for hospitalization for Parkinson's disease-related complications, US research shows. [More]

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]

Antibiotic choices critical for elderly with bloodstream infections

Failure to treat patients with bacteremia with an appropriate antibiotic is particularly harmful in elderly patients, report researchers. [More]
Canine lymphoma treatment adds up to cystitis

Canine lymphoma treatment adds up to cystitis

High cumulative doses of the alkylator cyclophosphamide could be to blame for the development of sterile hemorrhagic cystitis in dogs being treated for lymphoma, indicate the results of a US study. [More]